Trial · NCT06122285
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
NCT06122285, Recruiting, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD). Trials, record NCT06122285. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06122285
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
- NCT number
- NCT06122285
- Status
- Recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Conditions
- Hepatitis D
- Interventions
- Bulevirtide
- First posted
- 2023-11-08
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Describe the virological response to BLV in all patients starting BLV therapy for CHD | Month 6 | Percentage of patients with undetectable HDV RNA |
| Primary | Describe the virological response to BLV in all patients starting BLV therapy for CHD | Month 12 | Percentage of patients with ≥ 2 log IU/ml decline of HDV RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA | Month 6 | Proportion of patients with virological response, defined as a \>2 Log decline in HDV-RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA | Month 12 | Proportion of patients with virological response, defined as a \>2 Log decline in HDV-RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as undetectable HDV-RNA | Month 6 | Proportion of patients with virological response, defined as undetectable HDV-RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as undetectable HDV-RNA | Month 12 | Proportion of patients with virological response, defined as undetectable HDV-RNA |
| Secondary | Evaluation of the percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Month 6 | Percentage of patients with \>2 Log decrease in HDV-RNA along with normalization of ALT |
| Secondary | Evaluation of the percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Month 12 | Percentage of patients with \>2 Log decrease in HDV-RNA along with normalization of ALT |
| Secondary | Evaluation of the percentage of patients with normal ALT | Month 6 | Percentage of patients with normal ALT |
| Secondary | Evaluation of the percentage of patients with normal ALT | Month 12 | Percentage of patients with normal ALT |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06122285
GET https://conductscience.org/api/trials/v1/NCT06122285/registered?page=2